
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 5/1/24**
(See policy history boxes for previous effective dates)

Title: Measurement of Lipoprotein-Associated Phospholipase A₂ (Lp-PLA₂) and Secretory Type II Phospholipase A₂ (sPLA₂-IIA) in the Assessment of Cardiovascular Risk

Description/Background

LOW-DENSITY LIPOPROTEINS

Low-density lipoproteins (LDLs) have been identified as major atherogenic lipoproteins and have long been identified by the National Cholesterol Education Project as the primary target of cholesterol-lowering therapy. LDL particles consist of a surface coat composed of phospholipids, free cholesterol, and apolipoproteins surrounding an inner lipid core composed of cholesterol ester and triglycerides. Traditional lipid risk factors such as low-density lipoprotein-cholesterol LDL-C, while predictive on a population basis, are weaker markers of risk on an individual basis. Only a minority of subjects with elevated LDL and cholesterol levels will develop clinical disease, and up to 50% of cases of coronary artery disease (CAD) occur in subjects with “normal” levels of total and low-density lipoprotein cholesterol.

Treatment

Although treatment for elevated coronary disease risk with statins targets cholesterol levels, selection for treatment involves estimation of future CAD risk using well validated prediction models that use additional variables.

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂), also known as platelet-activating factor acetylhydrolase, is an enzyme that hydrolyzes phospholipids and is primarily associated with LDLs. Accumulating evidence has suggested that Lp-PLA₂ is a biomarker of CAD and may have a proinflammatory role in the progression of atherosclerosis. Recognition that atherosclerosis represents, in part, an inflammatory process has created considerable interest in measurement of proinflammatory factors as part of cardiovascular disease risk assessment.

Interest in Lp-PLA₂ as a possibly causal risk factor for CAD has generated development and testing of Lp-PLA₂ inhibitors as a new class of drugs to reduce risk of CAD. However, clinical trials of Lp-PLA₂ inhibitors have not shown significant reductions in CAD end points.^{1,2,3} Furthermore, assessment of Lp-PLA₂ levels has not been used in the selection or management of subjects in the clinical trials.

Regulatory Status

Lp-PLA₂

In December 2014, the PLAC® Test (diaDexus, San Francisco, CA), a quantitative enzyme assay, was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for Lp-PLA₂ activity. It was considered substantially equivalent to a previous version of the PLAC® Test (diaDexus), which was cleared for marketing by the Food and Drug Administration in July 2003. FDA product code: NOE.

sPLA₂-IIA

There are several manufacturers who produce testing kits for sPLA₂, including: ZEUS Scientific, antibodies-online, Biocompare, Cayman Chemical, Abcam, etc.

Medical Policy Statement

Measurement of lipoprotein-associated Phospholipase A2 (Lp-PLA₂) in the assessment of cardiovascular risk is considered experimental/investigational. While this service may be safe, its usefulness in the clinical management of atherosclerosis has not been established.

Measurement of secretory type II Phospholipase A2 (sPLA₂-IIA) to determine risk of cardiovascular disease is considered experimental/investigational. Current medical literature does not support a causal relationship between sPLA₂-IIA and cardiovascular disease.

Inclusionary and Exclusionary Guidelines

N/A

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

N/A

Other codes (investigational, not medically necessary, etc.):

83698

84999

Note: Individual policy criteria determine the coverage status of the CPT/HCPCS code(s) on this policy. Codes listed in this policy may have different coverage positions (such as established or experimental/investigational) in other medical policies.

Rationale

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Lipoprotein-Associated Phospholipase A₂ and Cardiovascular Risk

A large body of literature has accumulated on the utility of risk factors in the prediction of future cardiac events. The evidence assessed for this review consists of several systematic reviews of prospective cohort studies that have evaluated the association between lipoprotein-associated phospholipase A₂ (Lp-PLA₂) and cardiovascular outcomes.

The National Cholesterol Education Program (NCEP) ATP-III guidelines have indicated that to determine the clinical significance of Lp-PLA₂, the emerging risk factors should be evaluated against the following criteria⁴:

- Significant predictive power that is independent of other major risk factors
- A relatively high prevalence in the population (justifying routine measurement in risk assessment)
- Laboratory or clinical measurement must be widely available, well standardized, inexpensive, have accepted population reference values, and be relatively stable biologically.
- Preferable, but not necessarily, modification of the risk factor in clinical trials will have shown reduction in risk.

Clinical Context and Test Purpose

The purpose of Lp-PLA₂ testing in patients who have risk of cardiovascular disease (CVD) is to inform, improve patient stratification using risk prediction models that alter management decisions and improve health outcomes.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is individuals at risk for coronary artery disease (CAD).

Interventions

The relevant intervention of interest is testing for Lp-PLA₂ as a biomarker of CAD.

Comparators

The following practice is currently being used to manage CAD risk: standard assessment of cardiovascular risk.

Outcomes

The primary outcomes of interest are development of CVD such as CAD, stroke, and mortality. The development of CVD typically occurs over many years or decades.

Study Selection Criteria

For the evaluation of clinical validity of Lp-PLA₂ testing, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores)
- Included a suitable reference standard
- Patient/sample clinical characteristics were described
- Patient/sample selection criteria were described.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Lipoprotein-Associated Phospholipase A₂ as a Predictor of Coronary Artery Disease

Results of numerous, large-scale observational studies have examined whether Lp-PLA₂ is an independent risk factor for CAD. These observational studies have been analyzed in several systematic reviews.^{5,6,7} The largest, conducted by The Emerging Risk Factors Collaboration (2012), included 37 cohort studies and performed a patient-level meta-analysis of the association between novel lipid risk factors and cardiovascular risk over a median follow-up of 10.4 years in patients without CVD.⁵ The review found Lp-PLA₂ was an independent risk factor for cardiovascular events with a hazard ratio of 1.12 (95% confidence interval [CI], 1.09 to 1.21) for each 1 standard deviation increase in Lp-PLA₂ activity based on 11 studies (N=32075). However, there was no significant improvement in risk reclassification following the addition of Lp-PLA₂ to the reclassification model, with a net reclassification change of 0.21 (95% CI, -0.45 to 0.86).

Two other systematic reviews reported similar results. One review of 32 studies (N=79036) found for every 1 standard deviation increase in Lp-PLA₂ levels, the relative risk was 1.10 (95% CI, 1.04 to 1.17) for CAD, 1.08 (95% CI, 0.97 to 1.20) for stroke, and 1.16 (95% CI, 1.09 to 1.24) for vascular death, following adjustment for traditional risk factors. There was also a significant association between Lp-PLA₂ levels and nonvascular deaths (RR 1.10; 95% CI, 1.04 to 1.17).⁶ The second, smaller review (14 studies, N = 20,549) reported a pooled odds ratio of 1.60 (95% CI, 1.36 to 1.89), adjusted for traditional cardiac risk factors, for the development of future cardiac events with elevated Lp-PLA₂ levels.⁷

Section Summary: Clinically Valid

Several large meta-analyses found consistent evidence that Lp-PLA₂ level is an independent predictor of CAD. Based on these reviews, it is less clear the degree to which Lp-PLA₂ improves on existing CAD prediction models regarding clinically important magnitudes of reclassification.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

No studies were identified that assessed the clinical utility of Lp-PLA₂ test to define CAD risk.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Although the preceding studies showed that Lp-PLA₂ level is an independent risk factor for CAD, clinical utility depends on whether the use of Lp-PLA₂ levels improves on existing models of CAD prediction, which then translates into differences in treatment that improve patient outcomes. Establishing improved outcomes compared with existing prediction models could be demonstrated with clinical trials, but the expected difference in outcomes would probably be so small that the sample size of the trial would be impractically large. Decision modeling is another approach to estimating differences in patient outcomes due to the improved reclassification of risk. A robust, validated model using Lp-PLA₂ levels to predict CAD outcomes is necessary to use the test to manage patients. No studies identified evaluated whether a testing strategy that uses Lp-PLA₂ levels improves health outcomes.

Section Summary: Clinically Useful

Changes in patient management that could potentially occur with a strategy using Lp-PLA₂ levels are not well-established. Studies that directly evaluate patient management changes and/or health outcome improvements are needed to determine whether the use of Lp-PLA₂ measurement has efficacy in CVD. Alternatively, robust decision modeling studies may demonstrate clinically important changes in health outcomes by incorporating Lp-PLA₂

levels into CAD prediction models. Groups such as the American Heart Association have often incorporated results from decision models to inform their guidelines when the data underlying the models are robust. Incorporation of Lp-PLA₂ into decision models is necessary to demonstrate the potential clinical utility of the biomarker.

SUMMARY OF EVIDENCE

For individuals who have a risk of cardiovascular disease (CVD) who receive Lp-PLA₂ testing, the evidence includes studies of the association between Lp-PLA₂ and various CAD outcomes. Relevant outcomes are overall survival, disease-specific survival, and test validity. The studies have demonstrated that Lp-PLA₂ levels are an independent predictor of cardiovascular disease. Although Lp-PLA₂ levels are associated with cardiovascular disease risk, changes in patient management that would occur as a result of obtaining Lp-PLA₂ levels in practice are not well-defined. To demonstrate clinical utility, clinicians must have the tools to incorporate Lp-PLA₂ test results into existing risk prediction models that improve classification into risk categories alter treatment decisions and lead to improved health outcomes. Direct evidence for such improved health outcomes with Lp-PLA₂ testing in clinical practice is lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Group IIA Secretory Phospholipase A₂ (sPLA₂-IIA) and Cardiovascular Risk

Holmes et al (2013) investigated the role of secretory phospholipase A₂ (sPLA₂)-IIA in cardiovascular disease through a Mendelian randomization meta-analysis.¹² Nineteen general population studies (8,021 incident, 7,513 prevalent major vascular events [MVE] in 74,683 individuals) and 10 acute coronary syndrome (ACS) cohorts (2,520 recurrent MVE in 18,355 individuals) were reviewed using rs11573156, a variant in *PLA2G2A* encoding the sPLA₂-IIA isoenzyme, as an instrumental variable. Higher circulating levels of sPLA₂-IIA mass or sPLA₂ enzyme activity had been associated with increased risk of cardiovascular events. However, a causal association was not clear. There was an announcement made during the writing of the article that a phase III clinical trial of an sPLA₂ inhibitor (varespladib) had been stopped prematurely for lack of efficacy. The authors concluded that reduction of sPLA₂-IIA is unlikely to be a useful therapeutic target for prevention of cardiovascular events.

As a follow-up to the Holmes article, Talmud and Holmes (2015) discussed the efficacy of Mendelian randomization in validation of potential therapeutic targets before embarking on costly phase III trials.¹³ The clinical trial referenced in Holmes et al was further discussed. VISTA-16 tested whether inhibition of sPLA₂-IIA by varespladib reduced CHD and acute coronary syndrome. At the interim analysis, the independent data and safety monitoring board reviewed submitted data and the evidence showed the drug had no effect in comparison to placebo. The trial was terminated and further assessments of varespladib for CHD prevention were abandoned. The authors concluded that despite strong biological plausibility and compelling evidence from multiple observational studies, Mendelian randomization studies failed to show evidence of causation, which was borne out in the RCT.

Braamskamp et al (2013) reported on a study of 187 children with familial hypercholesterolemia (FH), aged 8 to 18 years, randomized to pravastatin or placebo. At baseline, median [IQR] sPLA₂-IIA mass and sPLA₂ activity levels were 7.2 [5.8–13.2] ng/ml and 36.4 [29.8–47.1] U/ml, respectively. Both sPLA₂-IIA mass and sPLA₂ activity were significantly correlated with high-sensitivity C-reactive protein ($r=0.33$, $p<.001$ and $r=0.386$,

$p < .001$, respectively), but not with other cardiovascular risk factors. Baseline levels of sPLA₂-IIA mass and sPLA₂ activity were not significantly associated with carotid intima-media thickness (cIMT) at baseline or at the end of follow-up. After two years, sPLA₂-IIA mass and sPLA₂ activity levels were not significantly reduced in the pravastatin group ($p = .20$ and $p = .63$, respectively), nor in the placebo group ($p = .17$ and $p = .11$, respectively). Changes from baseline did not differ between the treatment groups for sPLA₂-IIA mass ($p = .48$) and sPLA₂ activity ($p = .88$). The authors concluded that sPLA₂-IIA mass and sPLA₂ activity were not significantly associated with cIMT in our pediatric FH cohort. This could indicate that the potential predictive role of sPLA₂ as a biomarker of cardiovascular disease in children with FH is limited. Treatment with pravastatin did not reduce sPLA₂-IIA mass or sPLA₂ activity levels, as compared to placebo. Further studies with larger samples are required to address these issues.

In 2015, Akinkuolie et al performed an analysis of the JUPITER Trial (NCT00239681).¹⁴ The review's aim was to assess the role of sPLA₂-IIA in managing CVD risk in a primary prevention setting, and to assess future CVD risk relative to statin therapy. Participants with LDL cholesterol < 130 mg/dL and hsCRP ≥ 2 mg/L were randomized to rosuvastatin 20mg/day vs placebo. sPLA₂-IIA was quantified by sandwich-type ELISA (Cayman) in 11,269 participants before and 1 year after randomization. Cox regression was used to examine the association of sPLA₂-IIA with CVD. The impact of lifelong reduction in sPLA₂-IIA on CVD risk was assessed by Mendelian randomization analysis in 6,692 participants. The analysis concluded that while sPLA₂-IIA may be a measurable biomarker to assess the prognostic impact of inflammation on baseline and residual CVD risk, the results do not support sPLA₂-IIA as a viable pharmacological target for reducing CVD risk.

SUMMARY

Studies using sPLA₂-IIA reduction as a therapeutic target for prevention of cardiovascular events have not shown efficacy and have resulted in early termination. There is insufficient evidence of a causal relationship between sPLA₂-IIA and cardiovascular disease.

SUPPLEMENTAL INFORMATION

PRACTICE GUIDELINES AND POSITION I

American College of Cardiology and American Heart Association

In 2019, the American College of Cardiology and American Heart Association published joint guidelines on the assessment of cardiovascular risk in asymptomatic patients.⁸ Lp-PLA₂ testing was not mentioned in these guidelines, which was a change from 2010 guidelines.⁹ In the prior guideline, Lp-PLA₂ was given a lib recommendation for assessing cardiovascular risk in intermediate-risk asymptomatic adults.

American Association of Clinical Endocrinologists and American College of Endocrinology

In 2012, the American Association of Clinical Endocrinologists and the American College of Endocrinology (2012) published guidelines on the management of dyslipidemia and prevention of atherosclerosis.^{10,11} These guidelines made the following recommendations for LpA-PLA₂ testing. (Table 1).

Table 1. Guidelines on Dyslipidemia and Atherosclerosis

Recommendation	GOE	LOE
Assess markers of inflammation in patients where further stratification of risk is necessary. Highly sensitive CRP (hsCRP) and Lp-PLA ₂ provide useful information in these instances and appear to be synergistic in predicting the risk of CVD and stroke.	B	1
Measure Lp-PLA ₂ , which in some studies has demonstrated more specificity than hsCRP, when it is necessary to further stratify a patient's CVD risk, especially in the presence of systemic highly sensitive CRP elevations	B	2

CRP: C-reactive protein; CVD: cardiovascular disease; GOE: grade of evidence; hsCRP: high-sensitivity C-reactive protein; LOE: level of evidence; Lp-PLA₂: lipoprotein-associated phospholipase A₂.

In 2017, an update to guidelines published jointly by the American Association of Clinical Endocrinologists and American College of Endocrinology (2017) recommended the measurement of Lp-PLA₂ as an additional indication of cardiovascular risk.¹⁰ Citing several studies in which Lp-PLA₂ was comparable with high-sensitivity CRP as a risk predictor, the guidelines accordingly recommended the use of Lp-PLA₂ data in situations requiring a more specific evaluation of risk of atherosclerotic cardiovascular disease that is provided by high-sensitivity CRP.

U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS

No U.S. Preventive Services Task Force recommendations on the use of Lp-PLA₂ in the assessment of cardiovascular risk have been identified.

ONGOING AND UNPUBLISHED CLINICAL TRIALS

A search of ClinicalTrials.gov did not identify any ongoing or unpublished trials that would likely influence this review.

Government Regulations

National:

There is no national coverage determination (NCD).

Local:

Wisconsin Physicians Service Insurance Corporation

Local Coverage Determination (LCD): MoIDX: Biomarkers in Cardiovascular Risk Assessment (L36523)

Original effective date 6/16/2016; Revision effective date 03/30/2023

[NOTE: due to the length of the LCD, only portions related to this policy are included]

Coverage Indications, Limitations, and/or Medical Necessity

This policy denies coverage for **all CV risk assessment panels**, except the basic lipid panel, for symptomatic (with signs and symptoms) patients with suspected or documented CV disease because panel testing is not specific to a given patient's lipid abnormality or disease. The policy indicates the medical indication(s) based on published scientific articles and consensus guidelines for individual lipid biomarkers that may be covered to characterize a given lipid abnormality or disease, to determine a treatment plan or to assist with intensification of therapy. Each individual lipid biomarkers must be specifically ordered and the reason for the test order documented in the patient's medical record. The policy denies coverage for all **non-lipid** biomarkers when used for CV risk assessment including but not limited to, biochemical, immunologic, hematologic, and genetic biomarkers for CV risk assessment regardless of whether ordered in a panel or individually.

The following biomarkers, when they are included in a CV risk assessment panel, are non-covered:

- Lipoprotein subclasses;
- LDL particles;
- Intermediate density lipoproteins;
- High density lipoprotein AI9LpAI and AI/All;
- Lipoprotein(a);
- Apolipoprotein B (Apo B), apo A-I and apo E;
- **Lipoprotein-associated phospholipase A2 (Lp-PLA2)**
- BNP
- Cystatin C
- Thrombogenic/hematologic actors
- Interleukin-6 (IL-6), tissue necrosis factor- a (TNF- a) , plasminogen activator inhibitor-1 (PAI-1) and IL-6 promoter polymorphism
- Free fatty acids
- Visfatin, angiotensin-converting enzyme 1 (ACE2) and serum amyloid A
- Microalbumin
- Myeloperoxidase (MPO)
- Homocysteine and methylenetetrahydrofolate reductase (MTHFR) mutation testing
- Uric acid
- Vitamin D
- White blood cell count

- Long-chain omega-3 fatty acids in red blood cell membranes
- Gamma-glutamyltransferase (GGT)
- Genomic profiling including CardiaRisk angiotensin gene
- Leptin, ghrelin, adiponectin and adipokines including retinol binding protein 4 (RBP4) and resistin
- Inflammatory markers including VCAM-1, P-selectin (PSEL) and E-selectin (ESEL)
- Cardiovascular risk panels

Note #1: There is no Medicare benefit for screening CV risk assessment testing for asymptomatic (without signs or symptoms of disease) patients. Screening asymptomatic patients for cardiovascular risk is statutorily excluded by Medicare and will not be addressed in this policy.

Note #2: FDA approval/clearance means that a test/assay has analytical and clinical validity. The FDA does not review clinical utility (that the test/assay demonstrates improved patient outcomes). To meet Medicare’s “reasonable and necessary” criteria for coverage, a test/assay must have proven clinical utility.

Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)

Lp-PLA2 is also known as platelet activating factor acetylhydrolase. This enzyme hydrolyzes phospholipids and is primarily associated with LDLs. It has been suggested that this enzyme has a proinflammatory role in the development of atherosclerosis. Studies show that Lp-PLA2 is an independent predictor of CV risk but fail to demonstrate improved health outcomes. To improve outcomes, studies must demonstrate how risk factors improve risk classification and change in physician practice to improve patient outcomes.

The NCEP ATP III panel concluded that routine measurement of inflammatory markers (including Lp-PLA2) for the purpose of modifying LDL-cholesterol goals in primary prevention is not warranted. In the 2010 ACCF/AHA guidelines for assessment of CV risk, the experts concluded “lipoprotein-associated phospholipase (Lp-PLA2) might be reasonable for cardiovascular risk assessment in intermediate risk asymptomatic adults”. However, at the current time, it is not known whether Lp-PLA2 concentrations are clinically effective for motivating patients, guiding treatment, or improving outcomes.

Wisconsin Physicians Service Insurance Corporation

Local Coverage Article: Billing and Coding: MoIDX: BIOMARKERS in Cardiovascular Risk Assessment (A57559)

Original Effective Date: 11/01/2019

Revision Effective Date: 01/01/2023

This article lists code 83698 as a covered code.

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

- Cardiovascular Risk Panels
 - Genetic Testing – Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart DiseaseLipoprotein Direct Measurement, Intermediate Density Lipoprotein (Retired)
 - Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
-

References

1. White HD, Held C, et al. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med*. May 01 2014;370(18):1702-11. PMID 24678955
2. O'Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. *JAMA*. Sep 10 2014; 312(10): 1006-15. PMID25173516
3. Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. *JAMA*. Jan 15 2014; 311(3): 252-62. PMID 24247616
4. National Institutes of Health, National Heart Lung and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (NIH Publication No. 01-3670). 2001; <https://www.nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf> 11/29/23.
5. Di Angelantonio E, Gao P, et al. Lipid-related markers and cardiovascular disease prediction. *JAMA*. Jun 20 2012;307(23):2499-2506. PMID 22797450
6. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. *Lancet*. May 1 2010;375(9725):1536-1544. PMID 20435228
7. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. *Mayo Clin Proc*. Feb 2007;82(2):159-165. PMID 17290721
8. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019 Sep 10;140(11):e596-e646. 2019;140(11):e649-e650. PMID: 30879355
9. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Dec 14 2010;56(25):e50-103. PMID 21144964
10. Jellinger PS, Handelsman Y, Rosenblit PD et al. American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of

- atherosclerosis. *Endocr Pract* 2017; 23(4):479-497. Doi: 10.4158/EP171764.GL. Epub 2017 Feb 3.
11. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. *Endocr Pract*. Apr 2017;23(Suppl 2):1-87. PMID 28437620
 12. Holmes MV, Exeter HJ, Folkersen L, Nelson CP, Guardiola M, Cooper JA, Sofat R, Boekholdt SM, Khaw KT, Li KW, Smith AJ, Van't Hooft F, Eriksson P, Franco-Cereceda A, Asselbergs FW, Boer JM, Onland-Moret NC, Hofker M, Erdmann J, Kivimaki M, Kumari M, Reiner AP, Keating BJ, Humphries SE, Hingorani AD, Mallat Z, Samani NJ, Talmud PJ; CARDIoGRAM Consortium. Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. *Circ Cardiovasc Genet*. 2014 Apr;7(2):144-50. Doi: 10.1161/CIRCGENETICS.113.000271. Epub 2014 Feb 21. PMID: 24563418; PMCID: PMC4212409.
 13. Talmud, P.J., & Holmes, M.V. (2015). Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 35, 2281–2289.
 14. Akintunde O. Akinkuolie, MBBS; Robert J. Glynn, PhD; Latha Padmanabhan, MSc; Paul M Ridker, MD; Samia Mora, MD, MHS. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial
 15. Wisconsin Physicians Service Insurance Corporation. Local Coverage Determination: MoIDX: Biomarkers in Cardiovascular Risk Assessment (L36523); Original effective date 06/16/2016; Revision effective date 03/30/2023.
 16. Wisconsin Physicians Service Insurance Corporation. Local Coverage Article: Billing and Coding: MoIDX: BIOMARKERS in Cardiovascular Risk Assessment (A57559); Original Effective date 11/01/2019, Revision effective date 01/01/2023.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 11/29/23, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
9/1/07	7/30/07	8/29/07	Joint policy established
9/1/08	7/3/08	7/3/08	Routine maintenance
11/1/09	8/18/09	8/18/09	Routine maintenance: change in name from Measurement of Lipoprotein-associated Phospholipase (Lp-PLA2) to Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in the Assessment of Cardiovascular Risk
11/1/10	8/28/10	8/17/10	Routine maintenance
11/1/11	8/16/11	8/16/11	Routine maintenance
5/1/14	2/24/14	3/3/14	Routine maintenance Policy reformatted to mirror BCBSA
3/1/16	12/10/15	12/10/15	Routine maintenance Added code 0423T
5/1/17	2/21/17	2/21/17	Routine maintenance Removed code 0423T
5/1/18	2/20/18	2/20/18	Routine maintenance
5/1/19	2/19/19		Routine maintenance Combined with "Secretory Type II Phospholipase A2 Testing" policy
5/1/20	2/18/20		Routine maintenance. Ref 41 added.
5/1/21	2/16/21		Routine maintenance
5/1/22	2/15/22		Routine maintenance Code 0423T deleted
5/1/23	2/21/23		Routine maintenance (jf) Vendor Managed: Avalon
5/1/24	2/20/24		Routine maintenance (jf) Vendor Managed: Avalon

Next Review Date: 1st Qtr, 2025

BLUE CARE NETWORK BENEFIT COVERAGE

POLICY: MEASUREMENT OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A₂ (LP-PLA₂) AND SECRETORY TYPE II PHOSPHOLIPASE A₂ (SPLA₂-IIA) IN THE ASSESSMENT OF CARDIOVASCULAR RISK

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Not covered.
BCNA (Medicare Advantage)	See Government Regulations section.
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.